Aspartame use and Parkinson’s disease: review of associated effects on neurotransmitters, oxidative stress, and cognition

References

• Magnuson BA, Burdock GA, Doull J, Kroes RM, Marsh GM, Pariza MW, et al. Aspartame: a safety evaluation based on current use levels, regulations, and toxicological and epidemiological studies. Crit Rev Toxicol. 2007;37(8):629–727. doi:10.1080/10408440701516184.
   PubMed Web of Science ®Google Scholar
• Choudhary AK, Pretorius E. Revisiting the safety of aspartame. Nutr Rev. 2017;75(9):718–30. doi:10.1093/nutrit/nux035.
   PubMed Web of Science ®Google Scholar
• Humphries P, Pretorius E, Naudé H. Direct and indirect cellular effects of aspartame on the brain. Eur J Clin Nutr. 2008;62(4):451–62. doi:10.1038/sj.ejcn.1602866.
   PubMed Web of Science ®Google Scholar
• Rycerz K, Jaworska-Adamu JE. Effects of aspartame metabolites on astrocytes and neurons. Folia Neuropathol. 2013;51(1):10–7. doi:10.5114/fn.2013.34191.
   PubMed Web of Science ®Google Scholar
• Sandhir R, Kaur K. Influence of ethanol on methanol-induced oxidative stress and neurobehavioral deficits. J Biochem Mol Toxicol. 2006;20(5):247–54. doi:10.1002/jbt.20141.
   PubMed Web of Science ®Google Scholar
• Czarnecka K, Pilarz A, Rogut A, Maj P, Szymańska J, Olejnik Ł, Szymański P. Aspartame-True or false? narrative review of safety analysis of general Use in products. Nutrients. 2021;13(6):1957. doi:10.3390/nu13061957.
   PubMed Web of Science ®Google Scholar
• Malik VS, Li Y, Pan A, Koning D, Schernhammer L, Willett E, et al. Long-Term consumption of sugar-sweetened and artificially sweetened beverages and risk of mortality in US adults. Circulation. 2019;139(18):2113–25. doi:10.1161/CIRCULATIONAHA.118.037401.
   PubMed Web of Science ®Google Scholar
• Pase MP, Himali JJ, Beiser AS, Aparicio HJ, Satizabal CL, Vasan RS, et al. Sugar- and artificially sweetened beverages and the risks of incident stroke and dementia: A prospective cohort study. Stroke. 2017;48(5):1139–46. doi:10.1161/STROKEAHA.116.016027.
   PubMed Web of Science ®Google Scholar
• Singh N, Singh Lubana S, Arora S, Sachmechi I. A study of artificial sweeteners and thyroid cancer risk. J Clin Med Res. 2020;12(8):492–8. doi:10.14740/jocmr4258.
   PubMedGoogle Scholar
• Azad MB, Abou-Setta AM, Chauhan BF, Rabbani R, Lys J, Copstein L, et al. Nonnutritive sweeteners and cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. Can Med Assoc J. 2017;189(28):E929–E939. doi:10.1503/cmaj.161390.
   PubMed Web of Science ®Google Scholar
• Xia R, Mao Z-H. Progression of motor symptoms in Parkinson’s disease. Neurosci Bull. 2012;28(1):39–48. doi:10.1007/s12264-012-1050-z.
   PubMed Web of Science ®Google Scholar
• Hayes MT. Parkinson’s disease and parkinsonism. Am J Med. 2019;132(7):802–7. doi:10.1016/j.amjmed.2019.03.001.
   PubMed Web of Science ®Google Scholar
• Ding W, Ding LJ, Li FF, Han Y, Mu L. Neurodegeneration and cognition in Parkinson’s disease: a review. Eur Rev Med Pharmacol Sci. 2015;19(12):2275–81.
   PubMed Web of Science ®Google Scholar
• Espay AJ, LeWitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson’s disease: the case for noradrenergic enhancement. Mov Disord. 2014;29(14):1710–9. doi:10.1002/mds.26048.
   PubMed Web of Science ®Google Scholar
• Politis M, Niccolini F. Serotonin in Parkinson’s disease. Behav Brain Res. 2015;277:136–45. doi:10.1016/j.bbr.2014.07.037.
   PubMed Web of Science ®Google Scholar
• Wichmann T. Changing views of the pathophysiology of parkinsonism. Mov Disord. 2019;34(8):1130–43. doi:10.1002/mds.27741.
   PubMed Web of Science ®Google Scholar
• Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827(1):65–75. doi:10.1016/j.jchromb.2005.04.023.
   PubMed Web of Science ®Google Scholar
• Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson’s disease. Front Neuroanat. 2015;9:91. doi:10.3389/fnana.2015.00091.
   PubMed Web of Science ®Google Scholar
• Ferrer I, Martinez A, Blanco R, Dalfó E, Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm. 2011;118(5):821–39. doi:10.1007/s00702-010-0482-8.
   PubMed Web of Science ®Google Scholar
• Mischley LK, Lau RC, Bennett RD. Role of diet and nutritional supplements in Parkinson’s disease progression. Oxid Med Cell Longev. 2017;2017:6405278. doi:10.1155/2017/6405278.
   PubMed Web of Science ®Google Scholar
• Abdel-Salam OME, Salem NA, Hussein SJ. Effect of aspartame on oxidative stress and monoamine neurotransmitter levels in lipopolysaccharide-treated mice. Neurotox Res. 2012;21(3):245–55. doi:10.1007/s12640-011-9264-9.
   PubMed Web of Science ®Google Scholar
• Ashok I, Sheeladevi R, Wankhar D. Acute effect of aspartame-induced oxidative stress in Wistar albino rat brain. J Biomed Res. 2015;29(5):390–6. doi:10.7555/JBR.28.20120118.
   PubMedGoogle Scholar
• Bergstrom BP, Cummings DR, Skaggs TA. Aspartame decreases evoked extracellular dopamine levels in the rat brain: an in vivo voltammetry study. Neuropharmacology. 2007;53(8):967–74. doi:10.1016/j.neuropharm.2007.09.009.
   PubMed Web of Science ®Google Scholar
• Coulombe RA, Sharma RP. Neurobiochemical alterations induced by the artificial sweetener aspartame (NutraSweet). Toxicol Appl Pharmacol. 1986;83(1):79–85. doi:10.1016/0041-008x(86)90324-8.
   PubMed Web of Science ®Google Scholar
• Dailey JW, Lasley SM, Burger RL, Bettendorf AF, Mishra PK, Jobe PC. Amino acids, monoamines and audiogenic seizures in genetically epilepsy-prone rats: effects of aspartame. Epilepsy Res. 1991;8(2):122–33. doi:10.1016/0920-1211(91)90080-y.
   PubMed Web of Science ®Google Scholar
• Goerss AL, Wagner GC, Hill WL. Acute effects of aspartame on aggression and neurochemistry of rats. Life Sci. 2000;67(11):1325–9. doi:10.1016/s0024-3205(00)00723-2.
   PubMed Web of Science ®Google Scholar
• Karstaedt PJ, Pincus JH. Aspartame use in Parkinson’s disease. Neurology. 1993;43(3 Pt 1):611–3. doi:10.1212/wnl.43.3_part_1.611.
   PubMed Web of Science ®Google Scholar
• Lapierre KA, Greenblatt DJ, Goddard JE, Harmatz JS, Shader RI. The neuropsychiatric effects of aspartame in normal volunteers. J Clin Pharmacol. 1990;30(5):454–60. doi:10.1002/j.1552-4604.1990.tb03485.x.
   PubMed Web of Science ®Google Scholar
• Perego C, De Simoni MG, Fodritto F, Raimondi L, Diomede L, Salmona M, et al. Aspartame and the rat brain monoaminergic system. Toxicol Lett. 1988;44(3):331–9. doi:10.1016/0378-4274(88)90172-5.
   PubMed Web of Science ®Google Scholar
• Torii K, Mimura T, Takasaki Y, Ichimura M. Effect of mealing on plasma and brain amino acid, and brain monoamine in rats after oral aspartame. Physiol Behav. 1986;36(4):759–64. doi:10.1016/0031-9384(86)90365-3.
   PubMed Web of Science ®Google Scholar
• Torii K, Mimura T, Takasaki Y, Ichimura M. Dietary aspartame with protein on plasma and brain amino acids, brain monoamines and behavior in rats. Physiol Behav. 1986;36(4):765–71. doi:10.1016/0031-9384(86)90366-5.
   PubMed Web of Science ®Google Scholar
• Yokogoshi H, Roberts CH, Caballero B, Wurtman RJ. Effects of aspartame and glucose administration on brain and plasma levels of large neutral amino acids and brain 5-hydroxyindoles. Am J Clin Nutr. 1984;40(1):1–7. doi:10.1093/ajcn/40.1.1.
   PubMed Web of Science ®Google Scholar
• Abd-Ellah HF, Abou-Zeid NRA, Nasr NM. The possible protective effect of N-acetyl-L-cysteine and folic acid in combination against aspartame-induced cerebral cortex neurotoxicity in adult male rats: a light and transmission electron microscopic study. Ultrastruct Pathol. 2018;42(3):228–45. doi:10.1080/01913123.2018.1440270.
   PubMed Web of Science ®Google Scholar
• Abdel-Salam OME, Salem NA, El-Shamarka MES, Hussein JS, Ahmed NAS, El-Nagar MES. Studies on the effects of aspartame on memory and oxidative stress in brain of mice. Eur Rev Med Pharmacol Sci. 2012;16(15):2092–101. doi:10.1007/s12640-011-9264-9.
   PubMed Web of Science ®Google Scholar
• Abhilash M, Alex M, Mathews VV, Nair RH. Chronic effect of aspartame on ionic homeostasis and monoamine neurotransmitters in the rat brain. Int J Toxicol. 2014;33(4):332–41. doi:10.1177/1091581814537087.
   PubMed Web of Science ®Google Scholar
• Abu-Taweel GM, Zyadah MA, Ajarem JS, Ahmad M. Cognitive and biochemical effects of monosodium glutamate and aspartame, administered individually and in combination in male albino mice. Neurotoxicol Teratol. 2014;42:60–7. doi:10.1016/j.ntt.2014.02.001.
   PubMed Web of Science ®Google Scholar
• Adaramoye OA, Akanni OO. Effects of long-term administration of aspartame on biochemical indices, lipid profile and redox status of cellular system of male rats. J Basic Clin Physiol Pharmacol. 2016;27(1):29–37. doi:10.1515/jbcpp-2014-0130.
   PubMedGoogle Scholar
• Amin SN, Hassan SS, Rashed LA. Effects of chronic aspartame consumption on MPTP-induced parkinsonism in male and female mice. Arch Physiol Biochem. 2018;124(4):292–9. doi:10.1080/13813455.2017.1396348.
   PubMed Web of Science ®Google Scholar
• Ashok I, Sheeladevi R. Biochemical responses and mitochondrial mediated activation of apoptosis on long-term effect of aspartame in rat brain. Redox Biol. 2014;2:820–31. doi:10.1016/j.redox.2014.04.011.
   PubMed Web of Science ®Google Scholar
• Bawazir AE, Bokhary LE. Study the chronic effect of aspartame on some neurotransmitters content and histological structure of cerebellar cortex in male albino rats. Adv Environ Biol. 2015;9(11):19–25.
   Google Scholar
• Christian B, McConnaughey K, Bethea E, Brantley S, Coffey A, Hammond L, et al. Chronic aspartame affects T-maze performance, brain cholinergic receptors and Na+, K+-ATPase in rats. Pharmacol Biochem Behav. 2004;78(1):121–7. doi:10.1016/j.pbb.2004.02.017.
   PubMed Web of Science ®Google Scholar
• Finamor IA, Ourique GM, Pês TS, Saccol EMH, Bressan CA, Scheid T, et al. The protective effect of N-acetylcysteine on oxidative stress in the brain caused by the long-term intake of aspartame by rats. Neurochem Res. 2014;39(9):1681–90. doi:10.1007/s11064-014-1360-9.
   PubMed Web of Science ®Google Scholar
• Iyyaswamy A, Rathinasamy S. Effect of chronic exposure to aspartame on oxidative stress in brain discrete regions of albino rats. J Biosci. 2012;37(4):679–88. doi:10.1007/s12038-012-9236-0.
   PubMed Web of Science ®Google Scholar
• Iyaswamy A, Kammella AK, Thavasimuthu C, Wankupar W, Dapkupar W, Shanmugam S, et al. Oxidative stress evoked damages leading to attenuated memory and inhibition of NMDAR-CaMKII-ERK/CREB signalling on consumption of aspartame in rat model. J Food Drug Anal. 2018;26(2):903–16. doi:10.1016/j.jfda.2017.11.001.
   PubMed Web of Science ®Google Scholar
• Lebda MA, Sadek KM, El-Sayed YS. Aspartame and soft drink-mediated neurotoxicity in rats: implication of oxidative stress, apoptotic signaling pathways, electrolytes and hormonal levels. Metab Brain Dis. 2017;32(5):1639–47. doi:10.1007/s11011-017-0052-y.
   PubMed Web of Science ®Google Scholar
• Lindseth GN, Coolahan SE, Petros TV, Lindseth PD. Neurobehavioral effects of aspartame consumption. Res Nurs Health. 2014;37(3):185–93. doi:10.1002/nur.21595.
   PubMed Web of Science ®Google Scholar
• Onaolapo AY, Onaolapo OJ, Nwoha PU. Aspartame and the hippocampus: revealing a bi-directional, dose/time-dependent behavioural and morphological shift in mice. Neurobiol Learn Mem. 2017;139:76–88. doi:10.1016/j.nlm.2016.12.021.
   PubMed Web of Science ®Google Scholar
• Romano M, Casacci F, De Marchi F, Pacei T, Esteve A, Lomuscio G, et al. Effects of aspartame and carbohydrate administration on human and rat plasma large neutral amino acid levels and rat brain amino acid and monoamine levels. J Nutr. 1989;119(1):75–81. doi:10.1093/jn/119.1.75.
   PubMed Web of Science ®Google Scholar
• Sharma RP, Coulombe RA. Effects of repeated doses of aspartame on serotonin and its metabolite in various regions of the mouse brain. Food Chem Toxicol. 1987;25(8):565–8. doi:10.1016/0278-6915(87)90015-9.
   PubMed Web of Science ®Google Scholar
• Spiers PA, Sabounjian L, Reiner A, Myers DK, Wurtman J, Schomer DL. Aspartame: neuropsychologic and neurophysiologic evaluation of acute and chronic effects. Am J Clin Nutr. 1998;68(3):531–7. doi:10.1093/ajcn/68.3.531.
   PubMed Web of Science ®Google Scholar
• Tilson HA, Hong JS, Sobotka TJ. High doses of aspartame have no effects on sensorimotor function or learning and memory in rats. Neurotoxicol Teratol. 1991;13:27–35. doi:10.1016/0892-0362(91)90024-q.
   Google Scholar
• Villareal LMA, Cruz RAM, Ples MB, Vitor RJS. Neurotropic effects of aspartame, stevia and sucralose on memory retention and on the histology of the hippocampus of the ICR mice (Mus musculus). Asian Pac J Trop Biomed. 2016;6(2):114–8. doi:10.1016/j.apjtb.2015.11.001.
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Wurtman RJ, Maher TJ. Effects of oral aspartame on plasma phenylalanine in humans and experimental rodents. Short note. J Neural Transm. 1987;70(1-2):169–73. doi:10.1007/BF01252517.
   PubMed Web of Science ®Google Scholar
• Fernstrom JD. Oral aspartame and plasma phenylalanine: pharmacokinetic difference between rodents and man, and relevance to CNS effects of phenylalanine. Short note. J Neural Transm. 1989;75(2):159–64. doi:10.1007/BF01677429.
   PubMed Web of Science ®Google Scholar
• Hjelle JJ, Dudley RE, Marietta MP, Sanders PG, Dickie BC, Brisson J, Kotsonis FN. Plasma concentrations and pharmacokinetics of phenylalanine in rats and mice administered aspartame. Pharmacology. 1992;44(1):48–60. doi:10.1159/000138873.
   PubMed Web of Science ®Google Scholar
• Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell. 2019;18(6):e13031. doi:10.1111/acel.13031.
   PubMed Web of Science ®Google Scholar
• Bjørklund G, Peana M, Maes M, Dadar M, Severin B. The glutathione system in Parkinson’s disease and its progression. Neurosci Biobehav Rev. 2021;120:470–8. doi:10.1016/j.neubiorev.2020.10.004.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice PS, Ang L, Guttman M, Rajput AH, Furukawa Y, Kish SJ. Nigral glutathione deficiency is not specific for idiopathic Parkinson’s disease. Mov Disord. 2003;18(9):969–76. doi:10.1002/mds.10486.
   PubMed Web of Science ®Google Scholar
• Garrido M, Tereshchenko Y, Zhevtsova Z, Taschenberger G, Bähr M, Kügler S. Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons. Acta Neuropathol. 2011;121(4):475–85. doi:10.1007/s00401-010-0791-x.
   PubMed Web of Science ®Google Scholar
• Liddell JR, White AR. Nexus between mitochondrial function, iron, copper and glutathione in Parkinson’s disease. Neurochem Int. 2018;117:126–38. doi:10.1016/j.neuint.2017.05.016.
   PubMed Web of Science ®Google Scholar
• Su L-J, Zhang J-H, Gomez H, Murugan R, Hong X, Xu D, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev. 2019;2019:5080843. doi:10.1155/2019/5080843.
   PubMed Web of Science ®Google Scholar
• Reichert CO, de Freitas FA, Sampaio-Silva J, Rokita-Rosa L, Barros P de L, Levy D, Bydlowski SP. Ferroptosis mechanisms involved in neurodegenerative diseases. Int J Mol Sci. 2020;21(22). doi:10.3390/ijms21228765.
   Web of Science ®Google Scholar
• Peña-Bautista C, Vento M, Baquero M, Cháfer-Pericás C. Lipid peroxidation in neurodegeneration. Clin Chim Acta. 2019;497:178–88. doi:10.1016/j.cca.2019.07.037.
   PubMed Web of Science ®Google Scholar
• Angelova PR, Horrocks MH, Klenerman D, Gandhi S, Abramov AY, Shchepinov MS. Lipid peroxidation is essential for α-synuclein-induced cell death. J Neurochem. 2015;133(4):582–9. doi:10.1111/jnc.13024.
   PubMed Web of Science ®Google Scholar
• Stokes AF, Belger A, Banich MT, Taylor H. Effects of acute aspartame and acute alcohol ingestion upon the cognitive performance of pilots. Aviat Space Environ Med. 1991;62(7):648–53.
   PubMedGoogle Scholar
• Zhang X, Gao F, Wang D, Li C, Fu Y, He W, Zhang J. Tau pathology in Parkinson’s disease. Front Neurol. 2018;9:809. doi:10.3389/fneur.2018.00809.
   PubMedGoogle Scholar